Second-look surgery in the management of epithelial ovarian carcinoma

K. C. Podratz, William Arthur Cliby

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The constructs for incorporating second-look surgery (SLL) in the treatment schema for ovarian epithelial carcinoma are being challenged. Although second-look surgery remains the hallmark for assessing disease status at the completion of adjuvant chemotherapy, its continued utility must demonstrate potential benefits in both the presence and absence of disease. While critics cite as unacceptable the recurrence rates (20-50%) after negative SLL, the patients so identified have demonstrated chemosensitivity and harbor optimal tumor volumes if present and possibly more biologically favorable tumors. These very characteristics should render negative SLL patients ideal candidates for consolidation therapy. Furthermore, age, histologic grade; and residual volume stratifies patients into high- and low- risk categories for recurrence after negative second lock and should further facilitate consolidation therapy selection. Similarly, longevity following positive SLL is correlated adversely to advancing age and the histologic grade and the residuum of the tumor identified at reexploration. Recognizing that age and grade are predetermined factors, aggressive secondary cytoreduction has the potential of extending longevity. The latter is supported by mathematical tumor kinetic models and several focused, large, single-institution retrospective analyses. Therefore, the value of SLL is apparent but the criteria for its continued utilization in advanced ovarian cancer should include its performance by appropriately trained surgeons and the availability of (and preferably prospective trials for) both consolidation and salvage therapy to which all patients would optimally be afforded access.

Original languageEnglish (US)
JournalGynecologic Oncology
Volume55
Issue number3 II
DOIs
StatePublished - 1994

Fingerprint

Second-Look Surgery
Carcinoma
Recurrence
Salvage Therapy
Neoplasms
Residual Volume
Adjuvant Chemotherapy
Tumor Burden
Ovarian Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Second-look surgery in the management of epithelial ovarian carcinoma. / Podratz, K. C.; Cliby, William Arthur.

In: Gynecologic Oncology, Vol. 55, No. 3 II, 1994.

Research output: Contribution to journalArticle

@article{6ac42ca3d2ab4231b4fb72ab1f6c58f1,
title = "Second-look surgery in the management of epithelial ovarian carcinoma",
abstract = "The constructs for incorporating second-look surgery (SLL) in the treatment schema for ovarian epithelial carcinoma are being challenged. Although second-look surgery remains the hallmark for assessing disease status at the completion of adjuvant chemotherapy, its continued utility must demonstrate potential benefits in both the presence and absence of disease. While critics cite as unacceptable the recurrence rates (20-50{\%}) after negative SLL, the patients so identified have demonstrated chemosensitivity and harbor optimal tumor volumes if present and possibly more biologically favorable tumors. These very characteristics should render negative SLL patients ideal candidates for consolidation therapy. Furthermore, age, histologic grade; and residual volume stratifies patients into high- and low- risk categories for recurrence after negative second lock and should further facilitate consolidation therapy selection. Similarly, longevity following positive SLL is correlated adversely to advancing age and the histologic grade and the residuum of the tumor identified at reexploration. Recognizing that age and grade are predetermined factors, aggressive secondary cytoreduction has the potential of extending longevity. The latter is supported by mathematical tumor kinetic models and several focused, large, single-institution retrospective analyses. Therefore, the value of SLL is apparent but the criteria for its continued utilization in advanced ovarian cancer should include its performance by appropriately trained surgeons and the availability of (and preferably prospective trials for) both consolidation and salvage therapy to which all patients would optimally be afforded access.",
author = "Podratz, {K. C.} and Cliby, {William Arthur}",
year = "1994",
doi = "10.1006/gyno.1994.1351",
language = "English (US)",
volume = "55",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3 II",

}

TY - JOUR

T1 - Second-look surgery in the management of epithelial ovarian carcinoma

AU - Podratz, K. C.

AU - Cliby, William Arthur

PY - 1994

Y1 - 1994

N2 - The constructs for incorporating second-look surgery (SLL) in the treatment schema for ovarian epithelial carcinoma are being challenged. Although second-look surgery remains the hallmark for assessing disease status at the completion of adjuvant chemotherapy, its continued utility must demonstrate potential benefits in both the presence and absence of disease. While critics cite as unacceptable the recurrence rates (20-50%) after negative SLL, the patients so identified have demonstrated chemosensitivity and harbor optimal tumor volumes if present and possibly more biologically favorable tumors. These very characteristics should render negative SLL patients ideal candidates for consolidation therapy. Furthermore, age, histologic grade; and residual volume stratifies patients into high- and low- risk categories for recurrence after negative second lock and should further facilitate consolidation therapy selection. Similarly, longevity following positive SLL is correlated adversely to advancing age and the histologic grade and the residuum of the tumor identified at reexploration. Recognizing that age and grade are predetermined factors, aggressive secondary cytoreduction has the potential of extending longevity. The latter is supported by mathematical tumor kinetic models and several focused, large, single-institution retrospective analyses. Therefore, the value of SLL is apparent but the criteria for its continued utilization in advanced ovarian cancer should include its performance by appropriately trained surgeons and the availability of (and preferably prospective trials for) both consolidation and salvage therapy to which all patients would optimally be afforded access.

AB - The constructs for incorporating second-look surgery (SLL) in the treatment schema for ovarian epithelial carcinoma are being challenged. Although second-look surgery remains the hallmark for assessing disease status at the completion of adjuvant chemotherapy, its continued utility must demonstrate potential benefits in both the presence and absence of disease. While critics cite as unacceptable the recurrence rates (20-50%) after negative SLL, the patients so identified have demonstrated chemosensitivity and harbor optimal tumor volumes if present and possibly more biologically favorable tumors. These very characteristics should render negative SLL patients ideal candidates for consolidation therapy. Furthermore, age, histologic grade; and residual volume stratifies patients into high- and low- risk categories for recurrence after negative second lock and should further facilitate consolidation therapy selection. Similarly, longevity following positive SLL is correlated adversely to advancing age and the histologic grade and the residuum of the tumor identified at reexploration. Recognizing that age and grade are predetermined factors, aggressive secondary cytoreduction has the potential of extending longevity. The latter is supported by mathematical tumor kinetic models and several focused, large, single-institution retrospective analyses. Therefore, the value of SLL is apparent but the criteria for its continued utilization in advanced ovarian cancer should include its performance by appropriately trained surgeons and the availability of (and preferably prospective trials for) both consolidation and salvage therapy to which all patients would optimally be afforded access.

UR - http://www.scopus.com/inward/record.url?scp=0028618541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028618541&partnerID=8YFLogxK

U2 - 10.1006/gyno.1994.1351

DO - 10.1006/gyno.1994.1351

M3 - Article

C2 - 7835796

AN - SCOPUS:0028618541

VL - 55

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3 II

ER -